Drug intelligence / Profile preview

DD-A279

Development stage: Preclinical
Lead developer: HLB Science
Modality: Small Molecules

Overview

DD-A279 is a small molecule therapeutic candidate currently in preclinical development by HLB Life Science for the treatment of Alzheimer's dementia. The compound is designed to target endotoxins and dementia-causing proteins, potentially addressing neuroinflammation and protein aggregation pathways associated with the progression of Alzheimer's disease. As of 2023, the program remains in the preclinical stage of development.

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on DD-A279.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DD-A279.

Explore the full profile